Last reviewed · How we verify
Buprenorphine LO — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Buprenorphine LO (Buprenorphine LO) — mads u werner. Buprenorphine acts as a partial agonist at mu-opioid receptors and an antagonist at kappa-opioid receptors.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Buprenorphine LO TARGET | Buprenorphine LO | mads u werner | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Buprenorphine LO CI watch — RSS
- Buprenorphine LO CI watch — Atom
- Buprenorphine LO CI watch — JSON
- Buprenorphine LO alone — RSS
Cite this brief
Drug Landscape (2026). Buprenorphine LO — Competitive Intelligence Brief. https://druglandscape.com/ci/buprenorphine-lo. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing